DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: EMEND

Summary for Tradename: EMEND

Patents:7
Applicants:2
NDAs:2
Suppliers: see list3
drug
patent expirations by year for
 EMEND

Pharmacology for Tradename: EMEND

Clinical Trials for: EMEND

Efficacy of Aprepitant (Emend®) in Children
Status: Recruiting Condition: Nausea; Vomiting; Childhood Cancer

Re-examination Study of EMEND (Aprepitant) (MK-0869-184 AM1)
Status: Completed Condition: Chemotherapy-induced Nausea and Vomiting

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
Status: Terminated Condition: Chemotherapy-Induced Nausea and Vomiting

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
Status: Completed Condition: Chemotherapy-Induced Nausea and Vomiting

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029)
Status: Recruiting Condition: Chemotherapy-induced Nausea and Vomiting

Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma
Status: Recruiting Condition: Chemotherapy-induced Nausea and Vomiting

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
Status: Completed Condition: Postoperative Nausea and Vomiting

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)
Status: Completed Condition: Chemotherapy-Induced Nausea and Vomiting (CINV)

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Status: Completed Condition: Lymphoma

A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)
Status: Completed Condition: Chemotherapy-Induced Nausea and Vomiting; Postoperative Nausea and Vomiting

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Jun 30, 2006RXNo5,538,982<disabled><disabled>
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Jun 30, 2006RXNo5,719,147<disabled>YY<disabled>
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Jun 30, 2006RXNo6,096,742<disabled>YY<disabled>
Merck
EMEND
aprepitant
CAPSULE;ORAL021549Jun 30, 2006RXNo8,258,132<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EMEND

Drugname Dosage Strength RLD Submissiondate
fosaprepitant dimeglumineInjection150 mg/vialEmend1/25/2012
fosaprepitant dimeglumineInjection115 mg/vialEmend1/25/2012
aprepitantCapsule40 mg, 80 mg and 125 mgEmend11/3/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc